Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07644559 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions modified Enrollment target: 180 to 185 · Study sites: 29 to 31 · Eligibility criteria expanded, about 22 words · 1 more Show 4 more changesShow less
    • Enrollment target: 180 to 185
    • Study sites: 29 to 31
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: 6 to 7
  2. Site contacts updated at 1 of 29 sitesv21
  3. Study sites: 28 to 29v20
  4. Trial sites expanded: 24 → 28 locationsv19
  5. Study sites: 23 to 24v18
Show 15 earlier versionsHide 15 earlier versions
  1. Site contacts updated at 8 of 23 sitesv17
  2. Study sites: 22 to 23v16
  3. Study sites: 21 to 22v15
  4. Study sites: 20 to 21v14
  5. Study sites: 19 to 20v13
  6. Study sites: 18 to 19v12
  7. Study sites: 17 to 18v11
  8. Study sites: 16 to 17v10
  9. Study sites: 15 to 16v9
  10. Study sites: 14 to 15v8
  11. Study sites: 13 to 14v7
  12. Study sites: 11 to 13v6
  13. Study sites: 10 to 11v5
  14. Study sites: 9 to 10v4
  15. Study sites: 8 to 9 Start date changed from estimate of Jun 2026 to Jun 16, 2026v3 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2026 to Jun 16, 2026
  1. Trial sites expanded: 1 → 8 locationsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Trial Details
NCT Number NCT07644559
Lead Sponsor Verastem, Inc.
Conditions Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Enrollment 185 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov